Highlights of BioNTech's updates to be presented at the ASCO Annual Meeting 2024: BioNTech has established a diversified clinical oncology pipeline based on its modular multi-platform approach. The Company is advancing more than 20 clinical programs in unmet medical need solid tumor indications, including mRNA-based immunotherapies, targeted therapies entailing cell therapies and antibody- drug conjugates (ADCs), and novel immunomodulators. These candidates are currently being evaluated in more than 30 clin ...

Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE (NASDAQ:BNTX, "BioNTech"))) have announced that their collaboration to advance T cell receptor (TCR) immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022. This extension will ...

MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, "BioNTech" or the "Company") held its Annual General Meeting ("AGM") today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today's AGM were approved by a large majority of the shareholders. "The past few years marked a leap in competence for BioNTech," said Helmut Jeggle, ...

| --- | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | st | | | | | | 1 Quarter 2024 | | | | | | | | | | | | Financial Results & Corporate Update | | | | | | | | | | | | May 6, 2024 | | | | | | | | | | | 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation ...

We are in the planning phase with our partner Genmab, so that we cannot disclose any specifics at this time. But you will hear more about this program sometime later this year. Operator Hi, Daina. So we have at the moment the clinical trial running in multiple indications, including also indications for single arm and combination. What we are going to update is -- on ASCO is on the cervical cancer and platinum-resistant ovarian cancer, and non-small-cell lung cancer trials. And you will see response data an ...

BioNTech's long-term outlook helped it shrug off a first-quarter loss and sinking revenue as demand for COVID-19 vaccines declined.CFO Jens Holstein said the drop for the shot was seasonal, and the company expected 90% of its revenue coming later in the year.Holstein noted that BioNTech has billions in cash on hand to drive the company's efforts into treatments for cancer. American depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading Monday after the COVID-19 vaccine make ...

GlaxoSmithKline Proceedings Overview Cash Flow Net cash used in operating activities for the three months ended March 31, 2024, was €317.3 million, comprising a loss before tax of €331.8 million, negative non-cash adjustments of €151.7 million, and a net positive change in assets and liabilities of €222.5 million. Non-cash items primarily included finance income as well as depreciation of property, plant and equipment and other intangible assets without cash-effect. The net positive change in assets and lia ...

Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soonPresented clinical data at the American Association for Cancer Research ("AACR") Annual Meeting for individualized and off-the-shelf mRNA-based cancer vaccine candidates b ...

We expect BioNTech SE (BNTX) to surpass expectations when it reports first-quarter 2024 results on May 6, before the opening bell.Let’s see how things have shaped up for the quarter to be reported.Factors at PlayBioNTech’s top line currently comprises sales of its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer (PFE) . The vaccine is approved in several countries and has been a key contributor to BioNTech’s top line.However, following the end of the pandemic, sales of BioNTech/P ...

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company"))) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once ...